• Investors
  • Contact
Iconovo
  • About us
    • Board of Directors
    • Management
    • Our Team
    • Sustainability
    • Career
  • Inhalers
    • ICOcap®​
    • ICOpre®​
    • ICOres®
    • ICOone®​
    • ICOone®​ Nasal
  • Development capabilities
    • Inhalers
    • Formulation
    • Pharmaceutical Analysis
  • Pipeline
  • News & Events
  • Partner with us

DCAT Week

Posted in May 2, 2026 by jerker.stigsson@cloomy.se

« BIO-Europe Spring 2026
RRD 2026 »
Experts in inhalation medicine

Iconovo develops inhalation medicines in strategic partnership with other pharmaceutical companies. Combining our diverse portfolio of patented dry powder inhalers with considerable drug formulation expertise, we have the capacity for end-to-end product development in this area.

Iconovo AB

Visiting address
Ideon, Delta 6 LUND
Ideongatan 3B

Postal address
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden

Press releases
Subscription
Follow us
  • LinkedIn

Copyright Iconovo AB - All Rights Reserved